Company Expands R&D Expertise as First Pentarin™ Advances into Clinical Studies for Treatment of Neuroendocrine Cancers
WATERTOWN, MA — January 27, 2016 —Tarveda Therapeutics, Inc., today announced the appointment of Leila Alland, M.D. to the position of Chief Medical Officer. Dr. Alland brings more than 15 years of pharmaceutical drug development experience with a focus on oncology including leadership roles in clinical development at AstraZeneca and Bristol-Myers Squibb.
“We are delighted that Leila is joining Tarveda as we ramp up our drug development activities. Leila’s deep experience in leading clinical drug programs adds to our capabilities and the breadth of our stellar team as we expand the development of our Pentarins to a number of solid tumor targets,” said Drew Fromkin, President and Chief Executive Officer of Tarveda Therapeutics. “Leila has a proven track record of developing oncology drugs including most recently advancing more than a dozen clinical-stage oncology programs in her previous role as Vice President and Head of Oncology Clinical Development at AstraZeneca. She will be invaluable as we advance Tarveda’s lead drug candidate, PEN-221, into Phase 1 clinical studies this year.”
Dr. Alland has broad experience as a clinical leader developing both small and large molecule oncology products including Doxil®, Pegintron®, Tasigna®, and Opdivo®. Dr. Alland most recently served as Vice President and Head of Oncology Early Clinical Development at AstraZeneca where she was instrumental in building a new Oncology Early Clinical Development unit in Boston, MA, and Cambridge, UK. At AstraZeneca, she led numerous clinical stage programs through Phase 1/2 development, including six first-in-human programs and a Phase 2 registration study supporting the approval of Tagrisso™. At BMS, Dr. Alland served as clinical head for multiple early phase oncology programs spanning tumor targeted and immuno-oncology therapies. Dr. Alland conducted her pediatric hematology and oncology training at Memorial Sloan Kettering Cancer Center and then joined the faculty of the Albert Einstein College of Medicine as Assistant Professor where her cancer biology research resulted in publications in Nature, Nature Genetics and Cell. She received her medical degree at New York University School of Medicine and her B.A. in Biology at the University of Pennsylvania.
“I am excited to be joining Tarveda as it executes on its mission to develop Pentarins, which I believe have strong potential to positively impact patients’ lives,” said Leila Alland M.D. “Pentarins represent a unique approach to addressing the penetration challenges of antibody drug conjugates in the treatment of solid tumor cancers. As the first of an impressive portfolio of Pentarins, PEN-221 holds promise as a novel cancer drug for patients with significant unmet needs. We have strong preclinical data and a targeted strategy to treat patients with neuroendocrine cancers whose tumors are most likely to respond to PEN-221. I’m looking forward to working with the accomplished members of the Tarveda team as we bring PEN-221 and other Pentarins into the clinic.”
Tarveda is also excited to announce that Mary Simcox, Ph.D. has joined as Vice President of Biology. Dr. Simcox brings to Tarveda more than 10 years of experience in cancer cell biology and pharmaceutical drug discovery and development, including her most recent role as Director of Biology for FORMA Therapeutics as well as previous senior R&D roles at Roche in cancer signaling, preclinical angiogenesis and Avastin® biomarkers. Her undergraduate and doctoral work were completed at the University of California at Davis.
Pentarins™ are miniaturized biologic drug conjugates that represent a novel approach for the treatment of patients with solid tumor cancers. With the Pentarin platform, Tarveda is developing therapeutics that incorporate innovative targeting moieties linked to potent cancer cell-killing payloads to treat solid tumors. Each Pentarin is engineered to penetrate deep into solid tumors to drive efficacy through the inherent design of the miniaturized drug conjugate itself and/or by applying the company’s proprietary platform techniques to create Pentarins with ideal therapeutic attributes including tuned pharmacokinetics and biodistribution, tumor accumulation, tumor penetration, and cancer cell uptake.
About Tarveda Therapeutics
Tarveda Therapeutics, Inc., is a biopharmaceutical company discovering and developing Pentarins™ as a new class of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniaturized biologic drug conjugate that targets the somatostatin receptor for treatment of patients with neuroendocrine cancers including small cell lung cancer. Tarveda’s strategy includes developing its own proprietary Pentarins as well as applying the Pentarin platform to enhance the effectiveness of the targeting moieties and payloads of pharmaceutical collaborators. Tarveda has attracted top-tier investors including Novo A/S, New Enterprise Associates, Flagship Ventures, NanoDimension, and Eminent Venture Capital.
For more information, visit www.tarveda.com.
DOXIL® is a registered trademark of ALZA Corporation. PEGINTRON® is a registered trademark of Merck & Co. TASIGNA® is a registered trademark of Novartis Pharmaceuticals. OPDIVO® is a registered trademark of Bristol-Myers Squibb Company. TAGRISSO™ is a trademark of AstraZeneca. AVASTIN® is a registered trademark of Genentech, Inc.